Clinical Trial

A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 11, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-28.
Trial Details
NCT Number NCT06912165
Lead Sponsor Zhejiang Wenda Pharma Technology LTD.
Conditions Brief Description of Focus of Study
Enrollment 140 participants
Start Date 2024-12-31
Primary Completion 2025-10-30 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-11